US and Europe Atopic Dermatitis Market: By Drug Class (Immunosuppressants, PDE-4 Inhibitor, Antihistamines, Antibiotics, Biologic Therapy, Calcineurin Inhibitors, Corticosteroids, Emollients, Others), By Route Of Administration (Injectables, Oral, Topical), By Distribution Channel (Hospital Pharmacies, Online pharmacies, Drug stores, Retail pharmacies) and Country

Purchase Option

$ 3100
$ 4600
$ 6900

US and Europe Atopic Dermatitis Market size was valued at USD x billion in 2022 and is poised to grow at a CAGR of x% from 2023-29. The U.S. and Europe atopic dermatitis market is growing at a significant CAGR due to change in lifestyle, increase in atopic dermatitis population, and pollution and climatic changes. Growing prevalence of the food allergies and growing focus on new therapies are the key factors drive the U.S. and Europe atopic dermatitis market growth. Furthermore, increase in use of pharmacological products in developed countries. Increase in R&D expenditure to develop novel biologics, and improvement in healthcare expenditure might increase the growth of U.S. and Europe atopic dermatitis market over the forecast period. However, the challenge is time to be taken in drug adoption, high price and legal regulations might hamper the growth of the market. Similarly, highly generalized nature of the atopic dermatitis market and lack of awareness on drug usage hinder the growth of U.S. and Europe atopic dermatitis market over the forecast period. Atopic dermatitis primarily effects in infants, children, and also rarely effects in the adult population. Atopic dermatitis is associated with inhalant allergies (such as hay fever), asthma, and chronic dermatitis. In atopic dermatitis condition, the skin becomes inflamed and extremely itchy, that causes cracking, redness, weeping, vesicle formation, swelling, scaling, and crushing. The common risk factors for atopic dermatitis are inhalant allergens, food allergens, exposure to harsh soaps and detergents, and cold weather, and sometimes it causes due to genetics or heritability. People living in dry climate are more likely to get affected with atopic dermatitis.

US and Europe Atopic Dermatitis Market Key Developments:

  • In March 2017, U.S. FDA approved Regeneron/Sanofi anti-Interleukin-4R-alpha mAb Dupixent (Dupilumab) used in the treatment of atopic dermatitis.
  • In February 2016, Otsuka Pharmaceutical Co., Ltd. and Medimetriks Pharmaceuticals, Inc. announced that they entered into a licensing agreement. The agreement provides Medimetriks, with development, marketing and manufacturing rights to OPA-15406 in the United States.

U.S. and Europe Atopic Dermatitis Market Dynamics

Various companies in atopic dermatitis market are focussed on partnerships with other companies to develop products. For instance, in October 2016, Allergan plc, successfully completed purchasing all outstanding shares of Vitae Pharmaceuticals, Inc., focussed on innovative development programs for dermatologic conditions. The completion of the Vitae acquisition added highly differentiated development compounds to Allergan medical dermatology pipeline. Furthermore, acquisitions take place in the atopic dermatitis space are accelerating the growth of the atopic dermatitis market. In July 2016, Leo Pharma acquired global license from AstraZeneca for monoclonal antibody tralokinumab that completed clinical phase 2b. In December 2016, Novartis acquired Ziarco Group Limited including ZPL389, an oral drug used in the treatment of atopic dermatitis. Launch of new products, new product approvals from U.S. and Europe regulatory bodies might increase the growth of U.S. and Europe atopic dermatitis market. For instance, in December 2016, The FDA approved Eucrisa (Crisaborole) ointment manufactured by Pfizer used in the treatment of mild to moderate eczema (atopic dermatitis) in patients with two years of age. The launch of new classes of drugs gives patients and healthcare professional  alternatives to other classes of drugs such as corticosteroids, and calcineurin inhibitors.

Us Europe Atopic Dermatitis Market Segmentation

By Drug Class

  • Immunosuppressants
  • PDE-4 Inhibitor
  • Antihistamines
  • Antibiotics
  • Biologic Therapy
  • Calcineurin Inhibitors
  • Corticosteroids
  • Emollients
  • Others

By Route Administration

  • Injectables
  • Oral
  • Topical

By Distribution Channel

  • Hospital pharmacies
  • Online pharmacies
  • Drug stores
  • Retail pharmacies

Frequently Asked Questions

The Europe Atopic Dermatitis Market size was valued at USD 4.02 billion in 2022

Sanofi (France) Galderma SA (Nestle) (Switzerland) Allergan (U.S.) Novartis AG (Switzerland) Bristol-Myers Squibb (U.S.) Bayer AG (Germany) Otsuka Pharmaceutical Co., Ltd (Japan)

The us and europe atopic dermatitis market segments are by drug class, by route of administration and distribution channel

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • Sanofi (France)
  • Galderma SA (Nestle) (Switzerland)
  • Allergan (U.S.)
  • Novartis AG (Switzerland)
  • Bristol-Myers Squibb (U.S.)
  • Bayer AG (Germany)
  • Otsuka Pharmaceutical Co., Ltd (Japan)
  • Regeneron Pharmaceuticals (U.S.),
  • Pfizer Inc. (U.S.),
  • Encore Dermatology, Inc. (U.S.),
  • Medimetriks Pharmaceuticals, Inc. (U.S.), and
  • LEO Pharma A/S (Denmark)

Adjacent Markets